Abstract: Methods and systems are provided for associating Media Access Control (MAC) addresses with public chargers of electric vehicles, also known as Electric Vehicle Supply Equipment (EVSE), using a statistical approach and leveraging big data from connected vehicles (CV) and charge point operators (CPO). The data products generated by the method described herein can be utilized by electric vehicles (EV) to identify the charging EVSE during a public charging event.

Abstract: A charger scoring system including a transceiver and a processor is disclosed. The transceiver may be configured to receive a vehicle information from a vehicle. The vehicle information may include a vehicle charging information and a vehicle geolocation information. The transceiver may be further configured to receive a charger information associated with a charger located at a charging station, and a charging station geolocation. The processor may be configured to determine a charging event by correlating the vehicle geolocation information and the charging station geolocation. The processor may further correlate the charger information with the vehicle charging information, responsive to determining the charging event. The processor may additionally estimate a charger reliability score associated with a charger based on the correlation between the charger information and the vehicle charging information. The processor may further transmit the charger reliability score to an external device.

Abstract: This invention is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions.

Abstract: This invention is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions.

Abstract: This invention is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions.

Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Abstract: The invention discloses compounds of formula II: and methods of making the compounds, which are VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Abstract: Processes to make compounds, including N-acylsulfonamide apoptosis promoters are disclosed.

Abstract: Disclosed herein are methods of making compounds which are agonists or antagonists of one or more of the individual receptors of the S1P receptor family.

Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Abstract: The invention discloses compounds of formula II: and methods of making the compounds, which are VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Abstract: Processes to make compounds, including N-acylsulfonamide apoptosis promoters are disclosed.

Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.